Evidence map›Paper›PMID 42835994›Full record

ArticleMolecular therapy. Oncology2026

FOXM1 drives cisplatin resistance in ovarian cancer through STIM1-mediated SOCE and STAT1 activation.

Tzu-Chien Lin, Meng-Ru Hsieh, Hieu Dac Hanh Nguyen, Sarinporn Visitsattapongse, Wen-Tai Chiu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tzu-Chien LinInstitute of Basic Medical Sciences, National Cheng Kung University, Tainan 701401, Taiwan.
Meng-Ru HsiehDepartment of Biomedical Engineering, National Cheng Kung University, Tainan 701401, Taiwan.
Hieu Dac Hanh NguyenDepartment of Biomedical Engineering, National Cheng Kung University, Tainan 701401, Taiwan.
Sarinporn VisitsattapongseDepartment of Biomedical Engineering, School of Engineering, King Mongkut's Institute of Technology Ladkrabang, Bangkok 10520, Thailand.
Wen-Tai ChiuInstitute of Basic Medical Sciences, National Cheng Kung University, Tainan 701401, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cisplatin resistance remains a major challenge in ovarian cancer, limiting treatment efficacy and reducing patient survival. While FOXM1 and calcium (Ca

Indexed as

cisplatin resistanceFOXM1interferon signalingovarian cancerSOCESTAT1STIM1

Identifiers

PMID42835994
PMCPMC13636337

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.